Get the Stockscreener App
8.00
2.79%
-0.23
Actuate Therapeutics Inc stock is traded at $8.00, with a volume of 51,957.
It is down -2.79% in the last 24 hours and up +8.11% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$8.23
Open:
$8.07
24h Volume:
51,957
Relative Volume:
1.54
Market Cap:
$156.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.52%
1M Performance:
+8.11%
6M Performance:
+7.53%
1Y Performance:
+0.00%
1-Day Range:
$7.92
$8.23
1-Week Range:
$6.85
$8.26
52-Week Range:
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.00 | 156.25M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - GlobeNewswire Inc.
Actuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher – Still a Buy? - Defense World
Bone Metastasis in Solid Tumors Market Set to Grow Substantially - openPR.com
Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS - Barchart.com
Will Actuate's Elraglusib Prove To Be A Game Changer In The Fight Against Aggressive Cancers? - RTTNews
Soft Tissue Sarcoma with Lung Metastases Treatment Market Size - openPR.com
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight - Barchart.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - Marketscreener.com
Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC - MarketScreener
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, - openPR.com
Growth Driver In The Locally Advanced Pancreatic Cancer Market 2 - News Channel Nebraska Southeast
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (NASDAQ:ACTU) - Seeking Alpha
Brokers Set Expectations for ACTU Q1 Earnings - Defense World
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR.com
WIN Consortium leading the future of precision cancer medicine - EurekAlert
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation - Nasdaq
Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer - TipRanks
Actuate Therapeutics Inc. (ACTU) reports earnings - Quartz
ACTUATE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Neuroblastoma Pipeline 2025: Key Companies, MOA, ROA, - openPR
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
Pancreatic And Bile Duct Cancer Drug Market Enhancing Cybersecurity and Cloud Integration for the Future - ExpressVartha
Actuate reports progress in pancreatic cancer trial By Investing.com - Investing.com Australia
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Actuate Announces Completion of Enrollment in a Phase 2 - GlobeNewswire
Actuate reports progress in pancreatic cancer trial - Investing.com India
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Yahoo Finance
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - Marketscreener.com
Adenoid Cystic Carcinoma Market: Analysis of Epidemiology, - openPR
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth? - simplywall.st
Actuate Therapeutics sets annual meeting for May 22 - MSN
How To Work With Trump, The Future Of US Life Sciences And More: Updates From BIO CEO & Investor - Scrip
Actuate Therapeutics' IPO Lock-up Period Expires Today - RTTNews
Certain Restricted Stock Units of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Stock Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Stock of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Actuate Therapeutics, Inc. to Hold Annual Meeting of Stockholders on May 22, 2025 - Armenian Reporter
Invesco BulletShares 2019 Corporate Bond ETF (NYSEARCA:BSCJ) Stock Price Down 0% – Here’s Why - Armenian Reporter
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):